Home» Circulars» Viewcirculars Back
 
Ethiopian FDA-Notification on Revision of GMP Inspection Validity Period
 

 

PxlNwLtrHeaderLogo

PXL/HO/Cir-009/2025-26                                            Date: 21.04.2025

Hyderabad

 

Subject: Ethiopian FDA-Notification on Revision of GMP Inspection Validity Period

We would like to inform all concerned that the Ethiopian Food and Drug Authority (EFDA), under the mandate of Proclamation No. 1112/2019, has revised its directive governing the inspection of pharmaceutical manufacturers to enhance the safety, quality, and efficacy of health products in accordance with international standards.

Key Updates from EFDA – Directive No. 1055/2025 (Replacing Directive No. 999/2024):

  1. GMP Re-inspection Frequency: The interval for re-inspection of GMP-compliant facilities has been reduced from 5 years to 3 years.
  2. Validity of Fees: The fees paid for GMP inspection or GMP waiver are now valid for 3 years from the date of receipt by EFDA.
  3. Re-inspection Requirement: Manufacturers currently holding a 5-year valid cGMP certificate (based on physical inspection) must now apply for re-inspection after 3 years as per the revised directive.

EFDA will be notifying the concerned applicants shortlyregarding re-application for cGMP validity compliance.

We urge all foreign pharmaceutical manufacturers exporting to Ethiopia to align with the updated requirements and initiate preparations for timely re-inspection to avoid regulatory delays.

We appreciate your cooperation in adhering to these updated guidelines.

Warm Regards,


Raja Bhanu

Director General

 

Encl: EFDA letter dt:14/04/2025